Crew Capital Management Ltd. Acquires 954 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Crew Capital Management Ltd. grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 24.1% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 4,913 shares of the biopharmaceutical company’s stock after buying an additional 954 shares during the period. Crew Capital Management Ltd.’s holdings in Gilead Sciences were worth $398,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in GILD. Clearbridge Investments LLC grew its stake in Gilead Sciences by 179.0% in the third quarter. Clearbridge Investments LLC now owns 4,543,985 shares of the biopharmaceutical company’s stock valued at $340,526,000 after acquiring an additional 2,915,141 shares during the period. abrdn plc grew its stake in Gilead Sciences by 89.0% in the fourth quarter. abrdn plc now owns 3,764,107 shares of the biopharmaceutical company’s stock valued at $304,930,000 after acquiring an additional 1,772,887 shares during the period. International Assets Investment Management LLC acquired a new stake in Gilead Sciences in the fourth quarter valued at approximately $133,584,000. AEGON ASSET MANAGEMENT UK Plc acquired a new stake in Gilead Sciences in the fourth quarter valued at approximately $63,971,000. Finally, Bailard Inc. grew its stake in Gilead Sciences by 9,100.7% in the third quarter. Bailard Inc. now owns 722,345 shares of the biopharmaceutical company’s stock valued at $54,133,000 after acquiring an additional 714,494 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

GILD has been the subject of a number of research reports. Truist Financial cut Gilead Sciences from a “buy” rating to a “hold” rating and reduced their price objective for the company from $91.00 to $82.00 in a research note on Thursday, February 22nd. Morgan Stanley reduced their price objective on Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating for the company in a research note on Friday. TD Cowen reduced their price objective on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research note on Friday. StockNews.com upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday. Finally, UBS Group dropped their target price on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. Eleven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $83.60.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $73.18, for a total value of $146,360.00. Following the sale, the insider now directly owns 100,936 shares in the company, valued at $7,386,496.48. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Performance

Gilead Sciences stock traded up $0.52 during mid-day trading on Monday, reaching $65.94. 7,837,944 shares of the company’s stock were exchanged, compared to its average volume of 7,481,453. The business’s fifty day simple moving average is $71.28 and its 200 day simple moving average is $76.25. The firm has a market capitalization of $82.10 billion, a PE ratio of 184.72, a P/E/G ratio of 1.29 and a beta of 0.19. Gilead Sciences, Inc. has a one year low of $64.63 and a one year high of $87.86. The company has a quick ratio of 0.72, a current ratio of 0.98 and a debt-to-equity ratio of 1.08.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.49) by $0.17. The firm had revenue of $6.69 billion for the quarter, compared to analyst estimates of $6.36 billion. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The business’s revenue was up 5.3% on a year-over-year basis. During the same period in the previous year, the company posted $1.37 earnings per share. On average, sell-side analysts expect that Gilead Sciences, Inc. will post 3.82 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be paid a $0.77 dividend. The ex-dividend date of this dividend is Friday, June 14th. This represents a $3.08 annualized dividend and a dividend yield of 4.67%. Gilead Sciences’s payout ratio is presently 855.56%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.